title: Fenofibrate improves postprandial chylomicron clearance in II B hyperlipoproteinemia.
abstract: In 11 patients with IIB hyperlipoproteinemia we studied fasting lipids, lipoproteins, lipoprotein-modifying enzymes, and postprandial lipid metabolism after a standardized oral fat load supplemented with vitamin A before and 12 weeks after treatment with fenofibrate, a third-generation fibric acid derivative. Fasting plasma cholesterol, triglycerides, low-density lipoprotein cholesterol decreased significantly (P < 0.05, P < 0.01, P < 0.01), high-density lipoprotein subfraction 3 cholesterol increased significantly (P < 0.05), and high-density lipoprotein subfraction 2 cholesterol remained unchanged. Postprandial lipemia, i.e., the integrated postprandial triglyceride concentrations corrected for the fasting triglyceride level, and postprandial chylomicron concentrations, as assessed by biosynthetic labeling of chylomicrons with retinyl palmitate, decreased by 40.6% and 60.1% (P < 0.05; P < 0.05), respectively. The activity of lipoprotein lipase (LPL) increased by 33.6% (P < 0.05); the increase in LPL during fenofibrate treatment was positively correlated with the increase in high-density lipoprotein cholesterol (r = 0.84; P < 0.005). Hepatic lipase and cholesteryl ester transfer protein mass and activity remained unchanged. We conclude that lipid-lowering therapy with fenofibrate ameliorates fasting and, more profoundly, postprandial lipoprotein transport in hypertriglyceridemia by curbing postprandial triglyceride and chylomicron accumulation, at least in part, through an increase in LPL activity.
authors.affiliation: Abteilung für Klinische Atheroskleroseforschung, Universitätsklinik für Innere Medizin, Innsbruck, Austria.
authors.forename: B
authors.initials: B
authors.lastname: Föger
authors.forename: H
authors.initials: H
authors.lastname: Drexel
authors.forename: T
authors.initials: T
authors.lastname: Hopferwieser
authors.forename: G
authors.initials: G
authors.lastname: Miesenböck
authors.forename: A
authors.initials: A
authors.lastname: Ritsch
authors.forename: M
authors.initials: M
authors.lastname: Lechleitner
authors.forename: G
authors.initials: G
authors.lastname: Tröbinger
authors.forename: J R
authors.initials: JR
authors.lastname: Patsch
mesh_terms: D000328:Adult; D002352:Carrier Proteins / Q000097:blood; D053480:Cholesterol Ester Transfer Proteins; D002788:Cholesterol Esters / Q000097:blood; D002914:Chylomicrons / Q000097:blood* / Q000187:drug effects*; D004041:Dietary Fats / Q000008:administration & dosage; D004435:Eating / Q000502:physiology; D005260:Female; D011345:Fenofibrate / Q000494:pharmacology* / Q000627:therapeutic use; D006023:Glycoproteins; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood* / Q000188:drug therapy / Q000201:enzymology; D008055:Lipids / Q000097:blood; D008071:Lipoprotein Lipase / Q000097:blood; D008297:Male; D008875:Middle Aged; D013997:Time Factors
chemical_list: C506642:CETP protein, human; D002352:Carrier Proteins; D053480:Cholesterol Ester Transfer Proteins; D002788:Cholesterol Esters; D002914:Chylomicrons; D004041:Dietary Fats; D006023:Glycoproteins; D008055:Lipids; D008071:Lipoprotein Lipase; D011345:Fenofibrate